Antagonist Protocol in Poor Responders

Phase 4CompletedNCT02195947

Cairo University141 enrolled

Overview

The effect of use of the growth hormone with antagonist protocol on the outcome of the IVF/ICSI cycles in poor responders.

Two groups of poor responder female patients planned to receive the antagonist IVF/ICSI protocol are randomized to whether or not to add growth hormone to their protocol.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

141

Conditions

Female Infertility Due to Diminished Ovarian Reserve

Interventions

Growth HormoneDRUG

Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * females fulfilling the criteria of the ESHRE consensus 2011: * at least two of the following three features must be present: * dvanced maternal age (≥40 years) or any other risk factor for POR * previous POR (≤3 oocytes with a conventional stimulation protocol) * an abnormal ovarian reserve test (i.e. AFC ,5-7 follicles or AMH ,0.5 -1.1 ng/ml). Exclusion Criteria: * women who suffer from any other cause of infertility other than poor ovarian reserve * refusal of the patient to consent for using her data in the study.

Locations (1)

Kasr Al Aini

Cairo, Egypt

Outcomes

Primary Outcomes

Live birth rate

Time frame: Up to 9 months

Secondary Outcomes

Clinical pregnancy rate

Time frame: Up to 5 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.